COMMUNIQUÉS West-GlobeNewswire

Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year
25/02/2026
In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M NEW HAVEN, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO [...]
Baba Emerges from Stealth with Over $6.5 Million in Seed Funding to Expand Medicare-Covered Patient Advocacy for Older Adults
25/02/2026
Public debut includes Medicare- and Medicare Advantage-covered advocacy model and forthcoming Johns Hopkins clinical study NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Baba , a Medicare- and Medicare Advantage-covered [...]
AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026
25/02/2026
OCALA, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead [...]
Genmab to Participate in Upcoming Investor Conferences
25/02/2026
Media Release COPENHAGEN, Denmark; February 25, 2026 Genmab A/S (Nasdaq: GMAB ) announced today that members of its E xecutive Committee will participat e in fireside chats at the following investor conferences in March [...]
Zevra Therapeutics to Present at the Citizens Life Sciences Conference
25/02/2026
CELEBRATION, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Rgenta Therapeutics Presents Preclinical Data, Unveiling its New Drug Candidate, RGT-0474060, as a Promising Oral PMS1 Inhibitor for the Treatment of Huntington’s Disease
25/02/2026
Data demonstrating superior selectivity, safety and pharmacokinetics of RGT-0474060 were presented at the 21 st Annual Huntington’s Disease Therapeutics Conference (CHDI) being held this week in Palm Springs, CA Rgenta [...]
11 Presentations on Day 2 of Bionano Symposium 2026 Showcase Expanding Impact of Optical Genome Mapping Across Oncology and Cell & Gene Therapy
25/02/2026
SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 2 of Bionano Symposium 2026, which focused on New Frontiers in Oncology and Bioprocessing [...]
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
25/02/2026
AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and [...]
Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes
25/02/2026
Partnership will leverage Vivtex’s proprietary technologies built to identify optimal oral formulations for peptide and protein therapeutics with improved bioavailability Novo Nordisk will lead global development and [...]
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
25/02/2026
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of [...]
Lifeward to Acquire Powered Upper Body Exoskeleton with AI Capabilities Designed to Restore Function to Stroke Survivors
25/02/2026
IP and technology acquisition is expected to be highly accretive and to advance Lifeward’s position as a diversified biomedical innovation company Will Expand Lifeward’s portfolio beyond lower-limb solutions, creating a [...]
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
25/02/2026
NAARDEN, the Netherlands and MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Curanex Provides Operational Update on Key Regulatory Milestones
25/02/2026
Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a [...]
ITM to Announce Phase 3 COMPETE Trial Post-Hoc Subgroup Analysis in Pancreatic Neuroendocrine Tumors and Host Satellite Symposium at ENETS 2026
25/02/2026
Garching / Munich, February 25, 2026 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced that it will provide further exploratory and post-hoc subgroup analysis [...]
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
25/02/2026
Achieved $48 million and $184 million in RYTELO ® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous [...]
Effective Oral Steroids For Strength & Muscle Growth 2026: Legal Steroids For Sale" Smart Bodybuilders Use Crazy Bulk Steroid Alternatives.
25/02/2026
Legal Steroids For Sale 2026: Launched By Crazy Bulk" Steroids Alternatives for Cutting, Bulking, Body Building & Muscle Growth Safe Oral Steroids For Strength in USA. New York City, Feb. 25, 2026 (GLOBE NEWSWIRE [...]
Century Therapeutics to Participate in Upcoming Investor Conferences in March
25/02/2026
PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune [...]
YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform
25/02/2026
Taipei, Taiwan, Feb. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic [...]
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
25/02/2026
Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSU Topline data expected Q4 2026 BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE [...]

Pages